ArticleAmerican journal of hematology2017

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.

Liyanage P Perera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.